Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;29(3):590-594.
doi: 10.3201/eid2903.221546. Epub 2023 Feb 2.

Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022

Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022

Irina Kislaya et al. Emerg Infect Dis. 2023 Feb.

Abstract

After the rapid spread of SARS-CoV-2 BA.5 Omicron lineage in Portugal, we developed a seroepidemiologic survey based on a sample of 3,825 residents. Results indicated that from April 27 through June 8, 2022, the estimated seroprevalence of SARS-CoV-2 nucleocapsid or spike IgG was 95.8%, which indicates a high level of protection.

Keywords: 2019 novel coronavirus disease; BA.5; COVID-19; IgG; Omicron; Portugal; SARS-CoV-2; coronavirus disease; respiratory infections; seroepidemiological survey; seroprevalence; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Daily number of cases and percentages of SARS-CoV-2 seroprevalence in 4 serial seroepidemiologic surveys in Portugal, May 2020–June 2022. Tick marks correspond to the first day of the month.
Figure 2
Figure 2
Data collection sites for study of seroprevalence of specific SARS-CoV-2 antibodies during the Omicron BA.5 wave, Portugal, April–June 2022 (ISN4COVID-19 study). NUTSIII, territorial units for statistics level III.

Similar articles

Cited by

References

    1. Operational considerations for respiratory virus surveillance in Europe. [cited 2023 Jan 3]. https://www.ecdc.europa.eu/sites/default/files/documents/Operational-con...
    1. Kislaya I, Gonçalves P, Gómez V, Gaio V, Roquette R, Barreto M, et al.; ISN2COVID-19 Group. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19). Infect Dis (Lond). 2022;54:418–24. 10.1080/23744235.2021.2025421 - DOI - PubMed
    1. Kislaya I, Gonçalves P, Barreto M, Sousa R, Garcia AC, Matos R, et al.; ISNCOVID-19 Group. ISNCOVID-19 Group. Seroprevalence of SARS-CoV-2 infection in Portugal in May-July 2020: results of the first national serological survey (ISNCOVID-19). Acta Med Port. 2021;34:87–94. 10.20344/amp.15122 - DOI - PubMed
    1. Kislaya I, Gonçalves P, Ramalhete S, Barreto M, Torres AR, Gaio V, et al.; ISNCOVID-19 Group. SARS-CoV-2 seroprevalence following a large-scale vaccination campaign in Portugal: results of the National Serological Survey, September–November 2021. Acta Med Port. 2023;36:5–14. 10.20344/amp.18528 - DOI - PubMed
    1. National Institute of Health Doutor Ricardo Jorge. Genetic diversity of the novel coronavirus SARS-CoV-2 (COVID-19) in Portugal. August 23th 2022 report. Lisbon (Portugal): The Institute; 2022.

Substances